Walvax BioTech - Asset Resilience Ratio

Latest as of June 2025: 2.20%

Walvax BioTech (300142) has an Asset Resilience Ratio of 2.20% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥308.17 Million

≈ $45.09 Million USD Cash + Short-term Investments

Total Assets

CN¥14.00 Billion

≈ $2.05 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2022)

This chart shows how Walvax BioTech's Asset Resilience Ratio has changed over time. Check 300142 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Walvax BioTech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300142 stock market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥308.17 Million	2.2%
Total Liquid Assets	CN¥308.17 Million	2.20%

Asset Resilience Insights

Limited Liquidity: Walvax BioTech maintains only 2.20% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Walvax BioTech Industry Peers by Asset Resilience Ratio

Compare Walvax BioTech's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Shanghai Haoyuan Chemexpress Co. Ltd. A SHG:688131	Drug Manufacturers - Specialty & Generic	1.37%
Beijing New Oriental Star Petrochemical Engineering Co Ltd SHE:002755	Drug Manufacturers - Specialty & Generic	24.59%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Celltrion Pharm Inc KQ:068760	Drug Manufacturers - Specialty & Generic	12.49%
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	Drug Manufacturers - Specialty & Generic	26.36%
Heilongjiang ZBD Pharmaceutical Co Ltd SHG:603567	Drug Manufacturers - Specialty & Generic	0.00%
Zhejiang Anglikang Pharmaceutical Co Ltd Class A SHE:002940	Drug Manufacturers - Specialty & Generic	9.11%

Annual Asset Resilience Ratio for Walvax BioTech (2013–2022)

The table below shows the annual Asset Resilience Ratio data for Walvax BioTech.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	-0.25%	CN¥-38.16 Million ≈ $-5.58 Million	CN¥15.34 Billion ≈ $2.24 Billion	+0.08pp
2021-12-31	-0.33%	CN¥-45.05 Million ≈ $-6.59 Million	CN¥13.67 Billion ≈ $2.00 Billion	+0.17pp
2020-12-31	-0.50%	CN¥-48.19 Million ≈ $-7.05 Million	CN¥9.65 Billion ≈ $1.41 Billion	+0.18pp
2019-12-31	-0.68%	CN¥-47.52 Million ≈ $-6.95 Million	CN¥7.02 Billion ≈ $1.03 Billion	-0.12pp
2018-12-31	-0.56%	CN¥-40.24 Million ≈ $-5.89 Million	CN¥7.24 Billion ≈ $1.06 Billion	+0.29pp
2017-12-31	-0.84%	CN¥-49.59 Million ≈ $-7.26 Million	CN¥5.88 Billion ≈ $859.84 Million	+0.13pp
2016-12-31	-0.98%	CN¥-61.90 Million ≈ $-9.06 Million	CN¥6.32 Billion ≈ $925.40 Million	-1.43pp
2015-12-31	0.45%	CN¥28.10 Million ≈ $4.11 Million	CN¥6.26 Billion ≈ $915.72 Million	+0.54pp
2013-12-31	-0.09%	CN¥-5.60 Million ≈ $-819.25K	CN¥6.14 Billion ≈ $897.87 Million	--

pp = percentage points

About Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.88 Billion

CN¥19.70 Billion CNY

Market Cap Rank

#4958 Global

#828 in China

Share Price

CN¥12.32

Change (1 day)

+1.15%

52-Week Range

CN¥10.91 - CN¥16.00

All Time High

CN¥93.63